文摘
在一些慢性结节病,患者需要长时间,高得令人无法接受剂量的糖皮质激素来达到缓解症状。在这些情况下,corticosteroid-sparing药物可能是管理允许长期治疗糖皮质激素的副作用。本研究检视prednisolone-sparing治疗用药。在一个开放的研究中,分析了11例慢性结节病。在感应阶段,咪唑硫嘌呤x 2毫克公斤体重(BW)(1)(1)结合x天0.6 - -0.8毫克强的松公斤BW (1) x天(1)管理与强的松被减少到0.1毫克公斤BW (1) x(1) 2 - 3个月内。其次是21-22-month维护阶段2毫克咪唑硫嘌呤x (1) (1) x每公斤和0.1毫克强的松x(1)(1)每公斤。临床参数和免疫学研究的支气管肺泡灌洗(BAL)进行分析。所有的病人有显著的缓解症状和改善或决议生理、血清学和影像学结果没有遭受严重的负面影响。19-26 9 11例完成治疗后几个月,和2/11患者终止治疗8和12个月后,分别。八个病人缓解持续4 - 73个月。 Three relapses occurred after 8, 18, and 22 months. During the induction phase, BAL cell composition changed and their activity in terms of cytokine release was suppressed. This preliminary study suggests that azathioprine may be effective as a corticosteroid-sparing agent in long-term therapy of sarcoidosis, but a much larger study is necessary to give the definitive answer.